Study guide
11.3 Echocardiography, Cardiac MRI & Non-Invasive Cardiac Imaging
AACN Cardiac Medicine Certification CMC
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview and the CMC Test Plan
1.1 CMC Exam Format, Eligibility, Fees & Scoring 1.2 The CMC Test Plan: Four Domains and How to Study Them
2 Chapter 2: Acute Coronary Syndromes and Ischemic Heart Disease
2.1 Pathophysiology & Classification of Acute Coronary Syndromes 2.2 12-Lead ECG Localization & Cardiac Biomarker Trajectories 2.3 Acute Reperfusion Strategies & Nursing Management 2.4 Complications of Acute Myocardial Infarction 2.5 Chronic Coronary Disease, Hyperlipidemia and Lipid-Lowering Therapy
3 Chapter 3: Heart Failure, Cardiomyopathies, Pericardial and Valvular Disease
3.1 Acute Decompensated Heart Failure & Staging 3.2 Acute Cardiogenic Pulmonary Edema 3.3 Dilated, Hypertrophic, and Restrictive Cardiomyopathies 3.4 Acute Pericarditis, Cardiac Tamponade & Constrictive Pericarditis 3.5 Infective Endocarditis, Myocarditis and Rheumatic Heart Disease 3.6 Valvular Heart Disease: Stenosis & Regurgitation 3.7 Syncope: Cardiac Versus Non-Cardiac Causes and Workup
4 Chapter 4: Dysrhythmias, Conduction Disorders and Electrophysiologic Interventions
4.1 Atrial Fibrillation, Atrial Flutter & Supraventricular Tachycardias 4.2 Ventricular Arrhythmias & Cardiac Arrest Management 4.3 Atrioventricular Blocks & Intraventricular Conduction Delays 4.4 Temporary Pacing: Transcutaneous, Transvenous and Epicardial 4.5 Permanent Pacemakers, CRT and Device Troubleshooting 4.6 Implantable and Wearable Cardioverter Defibrillators 4.7 Catheter Ablation and Post-Ablation Nursing Care 4.8 Synchronized Cardioversion and Defibrillation
5 Chapter 5: Vascular Conditions and Vascular Interventions
5.1 Aortic Dissection, Aortic Aneurysms & Hypertensive Crises 5.2 Peripheral Artery Disease & Acute Limb Ischemia 5.3 Acute Venous Thrombosis, DVT and VTE Prophylaxis 5.4 Peripheral and Carotid Angiography and Interventions 5.5 Endovascular Aortic Repair: EVAR and TEVAR 5.6 Catheter-Directed Thrombolysis and Post-Intervention Vascular Complications
6 Chapter 6: Shock States and Mechanical Circulatory Support
6.1 Cardiogenic Shock Pathophysiology, Hemodynamics & Etiologies 6.2 Non-Cardiogenic Shock: Hypovolemic, Distributive and Obstructive 6.3 Multisystem Organ Dysfunction Syndrome 6.4 Intra-Aortic Balloon Pump Therapy & Waveform Optimization 6.5 Percutaneous & Surgical Mechanical Circulatory Support: Impella, VA-ECMO, LVAD
7 Chapter 7: Cardiac Procedures and Structural Heart Interventions
7.1 Diagnostic Cardiac Catheterization & Coronary Angiography Interpretation 7.2 Percutaneous Coronary Intervention: Stents, No-Reflow and Post-PCI Care 7.3 Structural Heart Interventions: TAVR, MitraClip, Pericardiocentesis 7.4 Post-Cardiac Surgery Management (>48 Hours) & Late Complications
8 Chapter 8: Cardiovascular Pharmacology
8.1 Inotropes, Vasopressors & Inodilators 8.2 Vasodilators & Antianginal Agents 8.3 Antiarrhythmic Agents: Vaughan Williams Classes I-IV 8.4 Anticoagulants, Antiplatelets, Thrombolytics & Reversal Agents 8.5 Diuretics and Decongestion Strategies 8.6 Guideline-Directed Medical Therapy for Heart Failure
9 Chapter 9: Non-Cardiovascular Conditions: Pulmonary
9.1 Acute Pulmonary Embolism 9.2 Acute Respiratory Failure and ARDS 9.3 Pleural Space Abnormalities: Pneumothorax, Effusion and Hemothorax 9.4 Pulmonary Hypertension and Right Ventricular Failure 9.5 Sleep-Disordered Breathing in Cardiac Patients
10 Chapter 10: Non-Cardiovascular Conditions: Endocrine, Renal, Hematologic, Neurologic and Behavioral
10.1 Diabetes Mellitus and Glycemic Control in Cardiac Care 10.2 Thyroid and Adrenal Disorders in the Cardiac Patient 10.3 Metabolic Syndrome and Cardiometabolic Risk 10.4 Coagulopathies: Heparin-Induced Thrombocytopenia, DIC and Bleeding Disorders 10.5 Anemia and Transfusion Management in Cardiac Patients 10.6 Acute Ischemic and Hemorrhagic Stroke in the Cardiac Patient 10.7 Acute Kidney Injury and Contrast-Associated Nephropathy 10.8 Chronic Kidney Disease and the Dialysis-Dependent Cardiac Patient 10.9 Electrolyte Imbalances and Dysrhythmia Risk 10.10 Substance Use, Withdrawal and Cardiac Effects 10.11 Non-Cardiac Chest Pain: Differential and Triage 10.12 Non-Cardiovascular Multisystem Complications in Cardiac Patients
11 Chapter 11: Monitoring and Diagnostics
11.1 Pulmonary Artery Catheterization & Hemodynamic Waveform Interpretation 11.2 Arterial Line Monitoring, Continuous Cardiac Output & ScvO2 11.3 Echocardiography, Cardiac MRI & Non-Invasive Cardiac Imaging 11.4 Stress Testing and Myocardial Perfusion Imaging 11.5 Remote Cardiovascular Monitoring and Ambulatory Rhythm Devices 11.6 Laboratory Testing in Cardiac Care 11.7 Arterial Blood Gases and Acid-Base Interpretation 11.8 Pulse Oximetry, Capnography and Chest Radiography
12 Chapter 12: Respiratory, Renal and Multisystem Therapeutic Interventions
12.1 Non-Invasive Ventilation in Cardiac Patients 12.2 Invasive Mechanical Ventilation and Heart-Lung Interactions 12.3 Renal Replacement Therapy: Hemodialysis, CRRT, SCUF and Ultrafiltration 12.4 Targeted Temperature Management After Cardiac Arrest 12.5 Palliative and End-of-Life Care in Advanced Cardiac Disease
11.3 Echocardiography, Cardiac MRI & Non-Invasive Cardiac Imaging
Key Takeaways Explain This Topic AI
Transthoracic Echocardiography (TTE) is the non-invasive frontline imaging modality for EF measurement and valvular hemodynamics, whereas Transesophageal Echocardiography (TEE) provides high-resolution visualization of posterior structures including left atrial appendage thrombus and endocarditis vegetations.
Diastolic dysfunction is classified using mitral inflow velocity (E/A ratio) and tissue Doppler annular velocity (e' wave); an E/e' ratio >14 signals pathologically elevated LV filling pressures.
Cardiac Magnetic Resonance (CMR) is the reference gold standard for RV volumes/mass and utilizes Late Gadolinium Enhancement (LGE) to distinguish ischemic scar (subendocardial/transmural) from non-ischemic etiologies (myocarditis, amyloidosis).
Coronary Artery Calcium (CAC) scoring via Non-Contrast CT quantifies atherosclerotic plaque burden (Agatston score >400 represents severe CAD risk).
Nuclear Myocardial Perfusion Imaging (SPECT/PET) differentiates reversible ischemia (stress defect that normalizes at rest) from fixed myocardial scar (persistent defect at both stress and rest).
Last updated: August 2026
Echocardiographic Modalities: TTE versus TEE
Echocardiography utilizes high-frequency ultrasound waves to evaluate cardiac structural anatomy, ventricular wall motion, ejection fraction, valve morphology, and continuous blood flow velocity profiles.
Transthoracic Echocardiography (TTE)
Modality Overview: Non-invasive bedside test using an external transducer positioned on the anterior chest wall (parasternal, apical, subcostal, and suprasternal views).
Primary Indications: Frontline diagnostic evaluation of unexplained dyspnea, heart failure, heart murmurs, suspected pericardial effusion/tamponade, and routine ejection fraction quantification.
Limitations: Image resolution can be significantly degraded by body habitus (obesity), severe chronic obstructive pulmonary disease (COPD / hyperinflated lungs), or chest wall deformities.
Transesophageal Echocardiography (TEE)
Modality Overview: Semi-invasive procedure where a specialized high-frequency ultrasound probe is inserted into the esophagus and stomach, placing the transducer in direct anatomical proximity to the posterior atrium and aorta without intervening lung or bone attenuation.
Primary Indications:
Detection of Left Atrial Appendage (LAA) Thrombus prior to cardioversion or catheter ablation in Atrial Fibrillation.
Diagnosis of Infective Endocarditis (identifying subtle valvular vegetations <2-5 mm, ring abscesses, or valvular perforation).
Evaluation of Prosthetic Heart Valve Dysfunction (paravalvular leaks, prosthetic thrombosis).
Assessment of Acute Aortic Syndromes (Aortic Dissection, intramural hematoma).
Intraoperative monitoring during cardiac surgery or structural heart interventions (TAVR, MitraClip).
Nursing Priorities: NPO for ≥ 6 hours pre-procedure; verify absence of esophageal strictures or varices; monitor conscious sedation (midazolam/fentanyl); apply topical pharyngeal anesthesia (cetacaine/lidocaine spray); monitor airway and pulse oximetry; maintain NPO post-procedure until pharyngeal gag reflex fully returns.
Loading diagram... Non-Invasive Cardiac Imaging Selection & Diagnostic Pathways
Ventricular Function & Valvular Doppler Hemodynamics
Echocardiography provides quantitative measurement of both systolic and diastolic performance as well as valve orifice metrics.
Systolic Function: Simpson's Biplane Rule
Method of Discs (Simpson's Biplane Rule): Recommended quantitative echocardiographic technique for measuring Left Ventricular Ejection Fraction (LVEF). Left ventricular endocardial borders are traced in orthogonal apical 4-chamber and 2-chamber views at end-diastole and end-systole. The software divides the LV lumen into a stack of 20 elliptical discs to calculate End-Diastolic Volume (EDV) and End-Systolic Volume (ESV): L V E F ( % ) = E D V − E S V E D V × 100 LVEF\ (\%) = \frac{EDV - ESV}{EDV} \times 100 L V EF ( % ) = E D V E D V − ES V × 100
LVEF Categorization: Normal (≥ 50%), Mildly Reduced (41–49%), Moderately Reduced (30–40%), Severely Reduced (<30%).
Diastolic Function Assessment
Diastolic dysfunction reflects impaired LV relaxation and increased passive chamber stiffness, leading to elevated filling pressures:
Pulsed-Wave (PW) Doppler Mitral Inflow: Measures blood flow velocity across the mitral valve during diastole:
E Wave: Peak velocity during early rapid diastolic filling.
A Wave: Peak velocity during late diastolic filling produced by atrial contraction.
E/A Ratio: Normal value is 0.8 to 2.0. An E/A ≤ 0.8 indicates impaired early relaxation; an E/A > 2.0 with rapid deceleration time indicates severe restrictive filling.
Tissue Doppler Imaging (TDI) e' Wave: Measures intrinsic velocity of mitral annular tissue movement during early diastole (e' wave).
E/e' Ratio: Dividing peak early blood inflow velocity (E) by peak early annular tissue velocity (e') cancels out the effect of LV relaxation, yielding a direct index of left ventricular end-diastolic filling pressure:
An E/e' Ratio > 14 (average of septal and lateral annulus) is a highly specific marker of pathologically elevated LV filling pressures (PAOP > 15 mmHg).
Valvular Doppler Hemodynamics Table
Lesion Primary Doppler Parameter Mild Stenosis Moderate Stenosis Severe Stenosis Criteria
Aortic Stenosis (AS) Peak Velocity (Vₘₐₓ); Mean Pressure Gradient; Aortic Valve Area (AVA) < 3.0 m/s; < 20 mmHg; > 1.5 cm² 3.0 - 4.0 m/s; 20 - 40 mmHg; 1.0 - 1.5 cm² ≥ 4.0 m/s ; ≥ 40 mmHg ; < 1.0 cm² (<0.6 cm²/m²)
Mitral Stenosis (MS) Mean Pressure Gradient; Mitral Valve Area (MVA) > 1.5 cm² (progressive, stage B) Gradient rises with severity Severe: MVA ≤ 1.5 cm² (stage C/D, pressure half-time ≥ 150 ms); very severe ≤ 1.0 cm² . Mean gradient (typically > 5–10 mmHg) is supportive, not defining
Cardiac Magnetic Resonance (CMR) Imaging
Cardiac Magnetic Resonance (CMR) provides unmatched spatial resolution and tissue characterization without ionizing radiation. It is the absolute clinical reference gold standard for quantifying Right Ventricular volumes, RV mass, and ejection fraction.
Late Gadolinium Enhancement (LGE) & Myocardial Viability
Intravenous gadolinium-based contrast agents distribute into extracellular space. Normal tightly packed, viable myocytes exclude gadolinium. In necrotic, fibrotic, or scarred myocardium, extracellular volume expands, causing delayed clearance (retention) of contrast imaged 10 to 15 minutes post-injection (Late Gadolinium Enhancement):
Ischemic LGE Pattern: Extends from the subendocardium outward toward the epicardium in a specific coronary artery vascular distribution.
Viability Threshold: The depth of transmural LGE predicts functional recovery following revascularization:
LGE <50% Transmural Depth: Indicates viable hibernating myocardium with a high probability of functional recovery post-PCI/CABG.
LGE >50% Transmural Depth: Indicates non-viable, transmural scar tissue with minimal to no likelihood of functional recovery post-revascularization.
Non-Ischemic LGE Patterns: Typically spare the subendocardium:
Acute Myocarditis: Patchy subepicardial or mid-wall enhancement, predominantly involving the inferolateral LV free wall.
Cardiac Amyloidosis: Diffuse, circumferential subendocardial LGE paired with rapid blood pool gadolinium clearance.
Hypertrophic Cardiomyopathy (HCM): Patchy mid-wall LGE restricted to the points of RV-LV anterior and posterior septal insertion.
Cardiac Computed Tomography (CT) and Nuclear Cardiology
Non-invasive imaging pathways incorporate advanced radiographic CT and nuclear radionuclide modalities for CAD risk evaluation and ischemia testing.
Cardiac CT & Coronary Artery Calcium (CAC) Scoring
Coronary Artery Calcium Scoring (Agatston Score): Non-contrast, ECG-gated cardiac CT that quantifies calcified atherosclerotic plaque within epicardial coronary arteries:
Score 0: No identifiable calcification (extremely low 10-year cardiovascular risk).
Score 1 – 99: Mild calcification.
Score 100 – 399: Moderate plaque burden.
Score ≥ 400 (or >75th percentile for age/sex): Severe atherosclerotic burden, predicting high risk of future acute coronary events.
Computed Tomography Coronary Angiography (CTCA): Contrast-enhanced ECG-gated CT providing 3D anatomical imaging of coronary lumens. High negative predictive value (>97%) makes CTCA ideal for ruling out CAD in low-to-intermediate risk emergency department chest pain patients.
Nuclear Cardiology: SPECT and PET Myocardial Perfusion Imaging
Myocardial Perfusion Imaging (MPI) utilizes radiotracers (Technetium-99m sestamibi/tetrofosmin for SPECT; Rubidium-82 or 18F-FDG for PET) injected at rest and during peak exercise or pharmacological stress (Adenosine, Regadenoson, Dobutamine):
SPECT Reversible Ischemia vs. Fixed Scar:
Reversible Ischemia (Inducible Ischemia): Radiotracer uptake defect is present during stress imaging, but completely normalizes (fills in) on resting images. Indicates significant coronary arterial stenosis causing flow limitation under demand, which will benefit from revascularization.
Fixed Perfusion Defect (Infarted Scar): Radiotracer uptake defect is present on stress imaging and persists unchanged on resting images. Represents necrotic myocardial scar.
PET Metabolic FDG Viability Scanning: Combines perfusion imaging with 18F-Fluorodeoxyglucose (FDG) metabolic imaging. Segments exhibiting reduced perfusion but preserved FDG glucose uptake ( "Perfusion-Metabolism Mismatch" ) represent hibernating viable myocardium that will recover contractile function post-revascularization.